文献速递乳腺癌

EORTC 10994/BIG 1-00 试验中严重感染与乳腺癌转移的相关性:探讨先天免疫作为乳腺癌肿瘤抑制因素的作用

Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer.
PubMed 文献 · Eur J Cancer · 2016-12-24

该研究利用 EORTC 10994/BIG 1-00 III 期试验中 1856 例接受新辅助化疗患者的数据,分析严重感染与无远处复发生存间期(DRFI)的关系,并评估 160 例患者治疗前活检中 IRF7 基因标签与 DRFI 及骨转移风险的关系。结果显示严重感染与 DRFI 无关(HR=0.99),而 IRF7 标签高水平与骨转移风险降低显著相关(HR=0.76)。

要点

  • 新辅助化疗期间严重感染与无远处复发生存间期无显著关联(HR=0.99,90% CI 0.81-1.20)。
  • IRF7 基因标签每增加 50 单位,DRFI 风险比 HR=0.89(90% CI 0.78-1.02,p=0.081),呈关联趋势。
  • IRF7 标签每增加 50 单位,骨转移风险显著降低(HR=0.76,95% CI 0.62-0.94,p=0.012)。

核心结论

  • 本研究表明,新辅助化疗期间的严重感染与无远处复发生存间期降低无关。
  • IRF7 基因标签高表达与骨复发风险降低显著相关。
  • 该结果可能对未来辅助双膦酸盐/地舒单抗的使用有帮助。

研究设计与样本

  • 研究使用欧洲癌症研究与治疗组织(EORTC)10994/BIG 1-00 III 期试验的临床数据,该试验于 2001 年至 2006 年间随机分配 1856 例接受新辅助化疗的患者。
  • 严重感染定义为新辅助化疗期间发热性中性粒细胞减少或任何其他 III-IV 级感染性不良事件。
  • IRF7 标签根据 160 例患者新辅助化疗前活检的基因表达数据计算。
  • 采用 Cox 模型分析无远处复发生存间期(DRFI),采用 Fine 和 Gray 模型研究骨转移作为首次远处复发的发生情况。

主要发现

  • 中位随访时间为 4.8 年。
  • 在全部合格患者(n=1615)中,未观察到严重感染与 DRFI 之间的关联(HR=0.99,90% CI 0.81-1.20)。
  • 对于 IRF7(N=160),观察到与 DRFI 关联的趋势(每增加 50 单位,HR=0.89,90% CI 0.78-1.02,p=0.081)。
  • IRF7 标签较高水平与骨转移风险降低显著相关(每增加 50 单位,HR=0.76,95% CI 0.62-0.94,p=0.012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones. METHODS: Clinical data of the European Organisation for Research and Treatment of Cancer 10994/BIG 1-00 phase III trial which randomised 1856 patients treated with NACT between 2001 and 2006, were used. Severe infection was febrile neutropenia or any other grade III-IV infective adverse event during NACT. The IRF7 signature was calculated from gene expression data available for 160 patients on a pre-NACT biopsy. Cox models for distant relapse-free interval (DRFI) investigated the effect of the severe infection and IRF7. Fine and Gray models studied the occurrence of bone metastases as first distant relapse. RESULTS: Median follow-up was 4.8 years. No association between severe infection and DFRI was observed in the entire population (n = 1615 eligible patients) hazard ratio [(HR] = 0.99, 90% CI, confidence interval [CI] = 0.81-1.20). For IRF7 (N = 160), a trend towards an association with DRFI was observed (HR = 0.89 for a 50 unit increase, 90% CI = 0.78-1.02, p = 0.081). Higher levels of the IRF7 signature were significantly associated with a decreased bone metastases risk: (HR = 0.76 for a 50 unit increase, 95% CI, 0.62-0.94, p = 0.012). CONCLUSIONS: In this study it was shown that severe infection during NACT was not associated with decreased DRFI while high expression of the IRF7 gene signature was significantly associated with reduced bone relapse. This result may be useful for future adjuvant bisphosphonate/denosumab use.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Touati N, Tryfonidis K, Caramia F, et al. Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. Eur J Cancer. 2016. PMID: 28027521. doi:10.1016/j.ejca.2016.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。